Form 4 for MNKD MANNKIND CORP
Accepted 2022-08-01 00:00:00 ET · period of report 2022-07-31 · accession 0001209191-22-043574 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-01 | 2022-07-31 | MNKD | Galindo Alejandro | EVP Endocrine Business Unit | P - Purchase | $2.93 | +5,000 | 781.7K | +0.6% | +$14.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 Par Value | 2022-07-31 | P | A | 5,000 | $2.93 | 781,690 | D | — | — |